Items tagged with Drug-resistant TB
New survey investigates levels of resistance to essential TB drugs (post)
Geneva, 11 July 2016 – The first ever multi-country population-based survey investigating levels of the resistance to essential tuberculosis (TB) drugs was published last week in The Lancet Infectious Diseases. This work was led by the World Health Organization (WHO), in collaboration with National TB Programmes, National TB Reference Laboratories and Supranational Reference Laboratories.
PNG based job opportunities: TB clinicians for 2017 (post)
The Burnet Institute is currently looking for experienced clinicians to join the response team for the drug-resistant TB outbreak in Daru, Papua New Guinea (PNG).
Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB (post)
Levofloxacin was safe and well tolerated in children with and without HIV in long-term use. The data provide additional support for its inclusion in paediatric TB treatment and prevention regimens. [1]
Shortened nine-month MDR-TB regimen works well in children and adolescents (post)
The nine-month Bangladesh regimen for treatment of multidrug-resistant tuberculosis (MDR-TB) was successful in 83% of children and adolescents in an observational trial conducted in francophone Africa, presented at TB2016. [1]
Universal treatment of multidrug-resistant TB is possible within current budgets with generic production (post)
Generic production could make novel multidrug-resistant tuberculosis (MDR-TB) regimens available for US $53–507 per treatment course according to data presented at TB2016.
Multidrug-resistant TB treatment in North Korea: is scale-up possible? (post)
Summary points
HIV not a super-spreader of drug-resistant TB (post)
While the human immunodeficiency virus (HIV) pandemic fuels tuberculosis (TB) outbreaks, it does not drive the development and transmission of multidrug-resistance in TB patients as previously suspected, according to a study published in eLife.
Multidrug-resistant TB prevention trials to begin (post)
Three recent clinical trials – VQUIN, TB-CHAMP, and PHOENIx – are focusing on preventing MDR-TB among household contacts of MDR-TB patients. Two trials, VQUIN and TB-CHAMP, are studying the efficacy of levofloxacin compared to placebo treatment among household contacts. The VQUIN trial enrolled its first subject on March 14, 2016, while the TB-CHAMP trial is set to begin enrollment in Q4 of 2016. The PHOENix trial is focused on testing the efficacy of delamanid versus isoniazid treatment, and is the least far along. PHOENIx has completed a successful pilot trial and hopes to begin enrollment sometime in 2017.
First govt-funded bedaquiline treatment for TB initiated in Mumbai (post)
The beginning of bedaquiline medication will be a boost in the fight against the bacterial infection which has caused a rising incidence of multidrug-resistant (MDR-) and extensively drug-resistant (XDR-)TB cases in Mumbai.
Living with drug-resistant TB in India (post)
It is searing hot in Katwa in India's West Bengal state as Nurjahan sits on the bed, gazing through the window at the dusty village road leading to her house.
Page 32 of 117 · Total posts: 0
←First 31 32 33 Last→